Clinical Publication
RSSArticles
-
Berdazimer Topical Gel (Zelsuvmi)
The U.S. Food and Drug Administration has approved the first and only prescription drug for the home treatment of molluscum contagiosum. Berdazimer, administered with a hydrogel, is a nitric oxide-releasing agent with antiviral properties.
-
Safety and Tolerability of Inclisiran
A pooled analysis of seven relatively short-term ORION studies of inclisiran vs. placebo for lowering low-density lipoprotein cholesterol that assessed safety and tolerability for up to six years showed that inclisiran has similar rates of adverse events, excluding injection site reactions, as placebo treatment and is associated with fewer major adverse cardiovascular events.
-
A Comparison of Acute Migraine Therapies Using Big Data
In a big data-driven observational study that compared 3 million treated migraine attacks captured from a migraine diary smartphone app, triptans were found to be the most efficacious treatment class. Among the triptans, eletriptan had the highest rate of success. Consistent with clinical practice and recent consensus statements, the success of triptans was followed by ergots and antiemetics.
-
Nitrates in Food Reduce Cardiovascular Risk
Dietary nitrates, such as in beetroot juice, improve the cardiovascular risk profile, lowering blood pressure and enhancing endothelial function.
-
Is Brain Impairment Following COVID-19 Hospitalization Worse Than for Other Severe Illnesses?
The authors of this prospective cohort study with matched controls found that long-term brain health following severe COVID-19 hospitalization was impaired but was similar to hospitalization from other severe diseases.
-
Sleeping Away Dementia
In this long-term observational study of sleep efficiency in the Framingham Heart Study population, researchers found a strong correlation between a decline in duration of slow-wave sleep during aging and the risk of incident dementia from all causes. However, a direct cause-and-effect relationship cannot be determined from this observational study.
-
Examining Microbiome Metabolites and Parkinson’s Disease
A Mendelian randomization study shows that trimethylamine N-oxide (TMAO) and its precursor metabolites are not associated with risk of Parkinson’s disease (PD) but have both positive and negative causal effects on some indicators of PD severity and progression.
-
Racing Against Depression and Anxiety: Measuring Running vs. Antidepressant Therapy
This prospective study blending randomization with preference compared a running program with antidepressant therapy in adults with depression or anxiety and showed an improvement in mental health in both arms. However, physical health parameters increased only in the running group.
-
Iptacopan Capsules (Fabhalta)
The U.S. Food and Drug Administration has approved the first oral drug to treat paroxysmal nocturnal hemoglobinuria (PNH). Iptacopan is a first-in-class oral selective inhibitor of complement factor B (C3 pathway). It is distributed by Novartis Pharmaceutical Corporation as Fabhalta.
-
Metformin Use Is Associated with Decreased Diabetes-Associated Dementia
In two recent cohort studies, metformin use was found to decrease the risk of developing dementia in older adults with type 2 diabetes mellitus.